Evaluating Osteogenic Differentiation of Osteoblastic Precursors Upon Intermittent Administration of PTH/IGFBP7

Parathyroid hormone (PTH) 1–34 is the first anabolic agent approved for the treatment of osteoporosis. Preclinical evidence shows a potential association between PTH and osteosarcoma. The mechanisms mediating the bone- and neoplasm-forming effects of PTH remain incompleted understood, few studies on...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Han, Tian, Yueyang, Lin, Yile, Huang, Qia, Xue, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019492/
https://www.ncbi.nlm.nih.gov/pubmed/35462909
http://dx.doi.org/10.3389/fphar.2022.839035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019492/
https://www.ncbi.nlm.nih.gov/pubmed/35462909
http://dx.doi.org/10.3389/fphar.2022.839035

Ejemplares similares